Dr. Kenneth Rasalan Dulnuan, MD

Dr. Dulnuan practices at New Hyde Park Endoscopy in Lake Success, New York.

Dr. Dulnuan's NPI, 1083870588, was assigned on August 4, 2008. Dr. Dulnuan holds New Jersey license 25MA10692000.

Dr. Dulnuan's primary practice is New Hyde Park Endoscopy, at 1991 Marcus Avenue, Lake Success, NY 11042. The practice phone is (317) 796-7565.

Dr. Dulnuan's primary practice is New Hyde Park Endoscopy in Lake Success, New York. Dr. Dulnuan is also affiliated with North Shore University Hospital. The medical group on file is Northwell Health Physician Partners Cardiology at Great Neck. Dmand AI also links Dr. Dulnuan to 1 more hospital, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dulnuan practices, 4 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Dulnuan's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dmand AI has Dr. Dulnuan's licenses on file in 2 states: New Jersey and Kentucky.

CMS data shows 666 Medicare services from Dr. Dulnuan across 10 procedure codes in 2024, for 197 Medicare patients. Medicare paid $58,173 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 197 Medicare patients who saw Dr. Dulnuan in 2024. The largest group is 65 to 74, with 69 patients. 75% of them have heart failure, and 75% have high blood pressure. 21% are also on Medicaid. Their average risk score is 2.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dulnuan's median patient age at 73, with 37% women.

In 2024, Dr. Dulnuan wrote 593 Medicare Part D claims for 120 patients. 76% of them were for generic drugs. CMS names the drug for 471 of them, across 21 drugs with 11 or more claims each, at $852,927 in total drug cost. In 2023, CMS named 689 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Dulnuan for performance year 2024, reported as part of a group. Dr. Dulnuan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dulnuan as offering telehealth.

Dmand AI links 4 papers to Dr. Dulnuan, published from 2019 to 2024. The most frequent topics are Heart-Assist Devices and Heart Failure. Dr. Dulnuan's most frequent co-authors are Maya E. Guglin, MD, PhD, Navin Rajagopalan, MD and Talal Salem Alnabelsi, MD.

CMS Open Payments shows 149 general payments to Dr. Dulnuan from 30 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 61% of the total. Abbott Laboratories paid the most, $5,178.